S. Abhyankar

发表

Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.

Jinlin Song, J. Zhao, C. Telford, 2019, Clinical therapeutics.

MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

M. Davids, Richard P Hermann, A. Mato, 2022, Future oncology.

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials

F. Saad, B. Tombal, C. Ivanescu, 2017, Prostate Cancer and Prostatic Diseases.

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

B. Tombal, Choung-Soo Kim, Y. Choi, 2017, Medicine.

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

J. Bono, A. Armstrong, C. Higano, 2017, Prostate Cancer and Prostatic Diseases.

Oncotargets and Therapy Dovepress

Fei Liu, Jun Liu, I. Puzanov, 2022 .

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

G. Gibney, E. Wu, C. Reyes, 2015, Cancer medicine.

Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia

M. Davids, I. Ringshausen, C. Telford, 2021, Leukemia & lymphoma.

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: a Systematic Review and Network Meta-analysis.

M. Davids, V. Leblond, A. Padhiar, 2020, Clinical therapeutics.

Comparative healthcare costs in patients with metastatic melanoma in the USA

V. Schabert, J. Munakata, C. Reyes, 2015, Melanoma research.

Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M. Davids, A. Mato, J. Sharman, 2021, Blood.

BRAF V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

I. Puzanov, A. Cohn, T. Riehl, 2022 .

Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.

C. Cheah, Yucai Wang, W. Jurczak, 2023, Journal of Clinical Oncology.